Last reviewed · How we verify
Uricase-PEG 20
At a glance
| Generic name | Uricase-PEG 20 |
|---|---|
| Sponsor | EnzymeRx |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II (PHASE3)
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy (PHASE3)
- Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid (PHASE2)
- Safety and Efficacy Study of Intravenous Uricase-PEG 20 (PHASE1)
- Safety and Efficacy Study of Intramuscular Uricase-PEG 20 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Uricase-PEG 20 CI brief — competitive landscape report
- Uricase-PEG 20 updates RSS · CI watch RSS
- EnzymeRx portfolio CI